Share This Article:

Serum Chlorine Level as a Possible Predictive Factor for Oxaliplatin-Induced Peripheral Neuropathy

Abstract Full-Text HTML Download Download as PDF (Size:249KB) PP. 44-51
DOI: 10.4236/pp.2012.31007    4,222 Downloads   8,130 Views  

ABSTRACT

Peripheral neuropathy is a major adverse event associated with oxaliplatin-based chemotherapy and is a major dose-limiting adverse event in clinical practice. However, some patients treated with oxaliplatin may show no or minimal peripheral neuropathy. These differences are still poorly understood. The data on patients with colorectal cancer who received oxaliplatin-based regimens between January 2005 and June 2010 at South Miyagi Medical Center were retrospectively retrieved from the medical records. We selected 51 patients, and factor analysis was performed. The serum chlorine (Cl) level at baseline was significantly higher in patients with a high frequency of peripheral neuropathy (106; range 104 - 107 vs. 104; range 101 - 104 mEq/L, p = 0.02). Principal component analysis showed the variables Cl, body mass index, status of liver metastasis, and status of lymph node metastasis were related to the incidence of peripheral neuropathy. Discriminant analysis showed the model had predicted 72.5% of peripheral neuropathy. An understanding of the patient’s characteristics could be useful for preventing or predicting oxaliplatin-induced peripheral neuropathy.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

S. Tanaka, N. Suzuki, A. Mimura, K. Kurosawa, Y. Murai, D. Saigusa, M. Gamoh, M. Sato and Y. Tomioka, "Serum Chlorine Level as a Possible Predictive Factor for Oxaliplatin-Induced Peripheral Neuropathy," Pharmacology & Pharmacy, Vol. 3 No. 1, 2012, pp. 44-51. doi: 10.4236/pp.2012.31007.

References

[1] C. Tournigand, T. Andre, E. Achille, G. Lledo, M. Flesh, D. Mery-Mignard, E. Quinaux, C. Couteau, M. Buyse, G. Ganem, B. Landi, P. Colin, C. Louvet and A. de Gramont, “FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study,” Journal of Clinical Oncology , Vol. 22, No. 2, 2004, pp. 229-237. doi: 10.1200/JCO.2004.05.113
[2] A. de Gramont, A. Figer, M. Seymour, M. Homerin, A. Hmissi, J. Cassidy, C. Boni, H. Cortes-Funes, A. Cervantes, G. Freyer, D. Papa-michael, N. Le Bail, C. Louvet, D. Hendler, F. de Braud, C. Wilson, F. Morvan and A. Bonetti, “Leucovorin and Fluorouracil with or without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer,” Journal of Clinical Oncology, Vol. 18, No. 16, 2000, pp. 2938-2947.
[3] R. M. Goldberg, D. J. Sargent, R. F. Morton, C. S. Fuchs, R. K. Ramanathan, S. K. Williamson, B. P. Findlay, H. C. Pitot and S. R. Alberts, “A Randomized Controlled Trial of Fluorouracil plus Leucovorin, Iri-notecan, and Oxaliplatin Combinations in Patients with Previously Untreated Metastatic Colorectal Cancer,” Journal of Clinical Oncology, Vol. 22, No. 1, 2004, pp. 23-30. doi: 10.1200/JCO.2004.09.046
[4] L. B. Saltz, S. Clarke, E. Diaz-Rubio, W. Scheithauer, A. Figer, R. Wong, S. Koski, M. Lichinitser, T. S. Yang, F. Rivera, F. Couture, F. Sirzen and J. Cassidy, “Bevacizu- mab in Combination with Oxaliplatin-Based Chemotherapy as First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study,” Journal of Clinical On-cology, Vol. 26, No. 12, 2008, pp. 2013-2019. doi: 10.1200/JCO.2007.14.9930
[5] J. Cassidy, S. Clarke, E. Diaz-Rubio, W. Scheithauer, A. Figer, R. Wong, S. Koski, M. Lichinitser, T.S. Yang, F. Rivera, F. Couture, F. Sirzen and L. Saltz, “Randomized Phase III Study of Capecitabine plus Oxaliplatin Compared with Fluorouracil/Folinic Acid plus Oxaliplatin as First-Line Therapy for Metastatic Colorectal Cancer,” Journal of Clinical Oncology, Vol. 26, No. 12, 2008, pp. 2006-2012. doi: 10.1200/JCO.2007.14.9898
[6] Y. Kidani, M. Noji and T. Tashiro, “Antitumor Activity of Platinum(II) Complexes of 1,2-Diamino-cyclohexane Isomers,” Gann, Vol. 71, No. 5, 1980, pp. 637-643.
[7] A. Ibrahim, S. Hirschfeld, M. H. Cohen, D. J. Griebel, G. A. Williams and R. Pazdur, “FDA Drug Approval Summaries: Ox-aliplatin,” Oncologist, Vol. 9, No. 1, 2004, pp. 8-12. doi: 10.1634/theoncologist.9-1-8
[8] L. Gamelin, M. Boisdron-Celle, A. Morel and E. Gamelin, “Oxaliplatin Neu-rotoxicity,” Bull Cancer, Vol. 93, Suppl. 1, 2006, pp. S17-22.
[9] L. Gamelin, M. Boisdron-Celle, R. Delva, V. Guerin- Meyer, N. Ifrah, A. Morel and E. Gamelin, “Prevention of Oxaliplatin-Related Neurotoxicity by Calcium and Mag- nesium Infusions: A Retrospective Study of 161 Patients Receiving Oxaliplatin Combined with 5-Fluorouracil and Leucovorin for Advanced Colorectal Cancer,” Clinical Cancer Research, Vol. 10, No. 12, Part 1, 2004, pp. 4055-4061.
[10] H. S. Hochster, A. Grothey and B. H. Childs, “Use of Calcium and Magnesium Salts to Reduce Oxaliplatin- Related Neurotoxicity,” Journal of Clinical Oncology, Vol. 25, No. 25, 2007, pp. 4028-4029. doi: 10.1200/JCO.2007.13.5251
[11] C. Gedlicka, W. Scheithauer, B. Schull and G. V. Kornek, “Effective Treatment of oxaliplatin-Induced Cumulative Polyneuropathy with Alpha-Lipoic Acid,” Journal of Clinical On-cology, Vol. 20, No. 15, 2002, pp. 3359-3361. doi: 10.1200/JCO.2002.99.502
[12] J. P. Durand, C. Brezault and F. Goldwasser, “Protection against Ox-aliplatin Acute Neurosensory Toxicity by Venlafaxine,” Anticancer Drugs, Vol. 14, No. 6, 2003, pp. 423-425. doi: 10.1097/00001813-200307000-00006
[13] J. P. Durand, G. Deplanque, V. Montheil, J. M. Gornet, F. Scotte, O. Mir, A. Cessot, R. Coriat, E. Raymond, E. Mitry, P. Herait, Y. Yataghene and F. Goldwasser, “Efficacy of Venlafaxine for the Prevention and Relief of Ox-aliplatin-Induced Acute Neurotoxicity: Results of EFFOX, a Randomized, Double-Blind, Placebo-Controlled Phase III Trial,” Annals of Oncology, No. 2011, pp.
[14] M. Penz, G. V. Kornek, M. Raderer, H. Ulrich-Pur, W. Fie-biger and W. Scheithauer, “Subcutaneous Adminis- tra-tion of Amifostine: A Promising Therapeutic Option in Patients with Oxaliplatin-Related Peripheral Sensitive Neuropathy,” Annals of Oncology, Vol. 12, No. 3, 2001, pp. 421-422. doi: 10.1023/A:1011184609963
[15] S. Cascinu, F. Graziano, F. Ferrau, V. Catalano, C. Massacesi, D. Santini, R. R. Silva, S. Barni, A. Zaniboni, N. Battelli, S. Siena, P. Giordani, D. Mari, A. M. Baldelli, S. Antognoli, R. Maisano, D. Priolo, M. A. Pessi, G. Tonini, S. Rota and R. Labianca, “Raltitrexed plus Oxaliplatin (TOMOX) as First-Line Chemotherapy for Metastatic Colorectal Cancer. A Phase II Study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD),” Annals of Oncology, Vol. 13, No. 5, 2002, pp. 716-720.
[16] W. S. Wang, J. K. Lin, T. C. Lin, W. S. Chen, J. K. Jiang, H. S. Wang, T. J. Chiou, J. H. Liu, C. C. Yen and P. M. Chen, “Oral Glutamine Is Effective for Preventing Ox-aliplatin-Induced Neuropathy in Colorectal Cancer Patients,” Oncologist, Vol. 12, No. 3, 2007, pp. 312-319. doi: 10.1634/theoncologist.12-3-312
[17] S. von Delius, F. Eckel, S. Wagenpfeil, M. Mayr, K. Stock, F. Kullmann, F. Obermeier, J. Erdmann, R. Schmelz, S. Quasthoff, H. Adelsberger, R. Bredenkamp, R. M. Schmid and C. Lersch, “Carbamazepine for Prevention of Ox-aliplatin-Related Neurotoxicity in Patients with Advanced Colorectal Cancer: Final Results of a Randomised, Con-trolled, Multicenter Phase II Study,” Invest New Drugs, Vol. 25, No. 2, 2007, pp. 173-180. doi: 10.1007/s10637-006-9010-y
[18] P. L. Mitchell, D. Goldstein, M. Michael, P. Beale, M. Friedlander, J. Zalcberg, S. White, J. A. Thomson and S. Clarke, “Addition of Gabapentin to a Modified FOLFOX Regimen Does Not Reduce Oxaliplatin-Induced Neuroto- xicity,” Clinical Colorectal Cancer, Vol. 6, No. 2, 2006, pp. 146-151. doi: 10.3816/CCC.2006.n.032
[19] M. W. Saif and S. Hashmi, “Successful Amelioration of Ox-aliplatin-Induced Hyperexcitability Syndrome with the Antiepileptic Pregabalin in a Patient with Pancreatic Cancer,” Cancer Chemotherapy and Pharmacology, Vol. 61, No. 3, 2008, pp. 349-354. doi: 10.1007/s00280-007-0584-7
[20] M. W. Saif, K. Syrigos, K. Kaley and I. Isufi, “Role of Pregabalin in Treatment of Oxaliplatin-Induced Sensory Neuropathy,” Anticancer Research, Vol. 30, No. 7, 2010, pp. 2927-2933.
[21] C. Tournigand, A. Cervantes, A. Figer, G. Lledo, M. Flesch, M. Buyse, L. Mineur, E. Carola, P. L. Etienne, F. Rivera, I. Chirivella, N. Perez-Staub, C. Louvet, T. Andre, I. Tabah-Fisch and A. de Gramont, “OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 with Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study,” Journal of Clinical Oncology , Vol. 24, No. 3, 2006, pp. 394-400. doi: 10.1200/JCO.2005.03.0106
[22] A. De Gramont, M. Krulik, J. Cady, B. Lagadec, J. E. Maisani, J. P. Loiseau, J. D. Grange, G. Gonzalez-Canali, B. Demuynck, C. Louvet, et al., “High-Dose Folinic Acid and 5-Fluorouracil Bolus and Continuous Infusion in Advanced Colorectal Cancer,” European Journal of Cancer and Clinical Oncology, Vol. 24, No. 9, 1988, pp. 1499-1503. doi: 10.1016/0277-5379(88)90341-0
[23] T. Shimizu, T. Satoh, K. Tamura, T. Ozaki, I. Okamoto, M. Fukuoka and K. Nakagawa, “Oxaliplatin/Fluorouracil/Leucovorin (FOLFOX4 and Modified FOLFOX6) in Patients with Refractory or Advanced Colorectal Cancer: Post-Approval Japanese Population Experience,” Interna-tional Journal of Clinical Oncology, Vol. 12, No. 3, 2007, pp. 218-223. doi: 10.1007/s10147-007-0658-x
[24] E. Jerremalm, M. Hedeland, I. Wallin, U. Bondesson and H. Ehrsson, “Oxaliplatin Degradation in the Presence of Chloride: Identification and Cytotoxicity of the Monochloro Monooxalato Complex,” Pharmaceutical Research, Vol. 21, No. 5, 2004, pp. 891-894. doi: 10.1023/B:PHAM.0000026444.67883.83
[25] S. Mani, M. A. Graham, D. B. Bregman, P. Ivy and S. G. Chaney, “Oxaliplatin: A Review of Evolving Concepts,” Cancer Invest, Vol. 20, No. 2, 2002, pp. 246-263. doi: 10.1081/CNV-120001152
[26] M. E. Alberto, M. F. Lucas, M. Pavelka and N. Russo, “The Degradation Pathways in Chloride Medium of the Third Generation Anticancer Drug Oxaliplatin,” Journal of Physical Chem-istry B, Vol. 112, No. 35, 2008, pp. 10765-10768. doi: 10.1021/jp800476b
[27] F. R. Luo, S. D. Wyrick and S. G. Chaney, “Cytotoxicity, Cellular Uptake, and Cellular Biotransformations of Oxaliplatin in Human Colon Carcinoma Cells,” Oncology Research, Vol. 10, No. 11-12, 1998, pp. 595-603.
[28] H. Adelsberger, S. Quasthoff, J. Grosskreutz, A. Lepier, F. Eckel and C. Lersch, “The Chemotherapeutic Oxaliplatin Alters Voltage-Gated Na(+) Channel Kinetics on Rat Sensory Neurons,” European Journal of Pharmacology, Vol. 406, No. 1, 2000, pp. 25-32. doi: 10.1016/S0014-2999(00)00667-1
[29] F. Grolleau, L. Gamelin, M. Boisdron-Celle, B. Lapied, M. Pelhate and E. Gamelin, “A Possible Explanation for a Neurotoxic Effect of the Anticancer Agent Oxaliplatin on Neu-ronal Voltage-Gated Sodium Channels,” Journal of Neu-rophysiology, Vol. 85, No. 5, 2001, pp. 2293-2297.
[30] M. Sakurai, N. Egashira, T. Kawashiri, T. Yano, H. Ikesue and R. Oishi, “Oxaliplatin-Induced Neuropathy in the Rat: Involvement of Oxalate in Cold Hyperalgesia But Not Mechanical Allodynia,” Pain, Vol. 147, No. 1-3, 2009, pp. 165-174. doi: 10.1016/j.pain.2009.09.003

  
comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.